In this episode our host Dr Sarah Drummond speaks with Dr Thomas Tull about pemphigus vulgaris: 

• The clinical features of pemphigus vulgaris and other variants of pemphigus.
 • The step-wise management of pemphigus vulgaris including an approach to managing severe disease and the use of rituximab and intravenous immunoglobulin . 

Resources and further reading:
• British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris, 2017 (https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.15930)
• European guidelines for the management of pemphigus vulgaris and foliaceous initiated by the European Academy of Dermatology and Venereology, 2020 (https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.16752)
• Rituximab and Covid-19 Risk – a single-centre cohort study (https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00004-8/fulltext)
• Phase 2 Study of efficacy and safety of Rilzabrutinib for patients with pemphigus vulgaris (https://pubmed.ncbi.nlm.nih.gov/35686647/)
• Phase 2 Study of the use of Efgartigimod for patients with pemphigus vulgaris and foliaceous (https://pubmed.ncbi.nlm.nih.gov/34608631/) 

Disclosure: Dr. Tull provides consultancy services for Argenx who market Efgartigimod, which has been referenced in Part 1 and 2 of this series.

Recorded date: 26 January 2024